Literature DB >> 8461950

Iatrogenic urogenital fistulae.

V C Onuora1, S al-Mohalhal, A M Youssef, M Patil.   

Abstract

Nineteen patients with iatrogenic urogenital fistulae were treated between 1985 and 1989. All resulted from obstetric and gynaecological surgery. Major symptoms were leakage of urine through the vagina, menouria and perineal dermatitis. The fistulae formed after treatment for benign conditions in 18 patients. Fistulae complicating cancer surgery were uncommon. All patients with uretero-vaginal fistulae underwent preliminary percutaneous nephrostomy. Twelve patients underwent reconstruction using either the Boari-Ockerblad flap (5), uretero-neocystostomy (4) or other techniques (3), all with excellent results. Most of the remaining patients had treatment elsewhere. We consider that preliminary diversion, followed by delayed reconstruction, is a valuable option in the management of uretero-vaginal fistulae.

Entities:  

Mesh:

Year:  1993        PMID: 8461950     DOI: 10.1111/j.1464-410x.1993.tb15913.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  5 in total

1.  What is your diagnosis?

Authors:  Hasan Terzi; Tayyar Alp Ozkan; Ahmet Kale
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-12-01

2.  Vesicovaginal and ureterovaginal fistulas: a review of 39 cases.

Authors:  R Y Akman; S Sargin; G Ozdemir; A Yazicioğlu; S Cetin
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

3.  Management of genital fistulas in patients with cervical cancer.

Authors:  C Emmert; U Köhler
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

4.  Management of iatrogenic ureteric injuries associated with gynecological surgery.

Authors:  Muhammad Rafique; M Hanif Arif
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

5.  Diagnosis and management of 365 ureteric injuries following obstetric and gynecologic surgery in resource-limited settings.

Authors:  Thomas J I P Raassen; Carrie J Ngongo; Marietta M Mahendeka
Journal:  Int Urogynecol J       Date:  2017-10-11       Impact factor: 2.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.